Aurinia Pharmaceuticals earnings release, May 7, 2026
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
ROCKVILLE, Maryland and EDMONTON, Alberta – May 7, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three months ended March 31, 2026 and provided an update on recent business progress.
Financial Results
• Total Revenue:
For the three months ended March 31, 2026, total revenue was $77.7 million, up 24% from $62.5 million in the same period of 2025. – Net Product Sales:
For the three months ended March 31, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $73.6 million, up 23% from $60.0 million in the same period of 2025. – License, Collaboration and Royalty Revenue:
For the three months ended March 31, 2026, license, collaboration and royalty revenue from Aurinia’s collaboration partner, Otsuka, was $4.1 million, up 64% from $2.5 million in the same period of 2025.
• Net Income:
For the three months ended March 31, 2026, net income was $34.4 million, up 48% from $23.3 million in the same period of 2025.
• Diluted Earnings per Share:
For the three months ended March 31, 2026, diluted earnings per share was $0.25, up 56% from $0.16 in the same period of 2025.
• Cash Flows from Operating Activities:
For the three months ended March 31, 2026, cash flows from operating activities were $32.6 million, up 2408% from $1.3 million in the same period of 2025.
Cash Position
As of March 31, 2026, Aurinia had cash, cash equivalents, restricted cash and investments of $378.8 million, compared to $398.0 million at December 31, 2025. For the three months ended March 31, 2026, cash outflows from financing activities were $53.7 million, which included the repurchase of 2.5 million of the Company’ s common shares for $36.2 million and tax withholding payments related to net settlements of equity awards of $14.6 million.
2026 Total Revenue and Net Product Sales Guidance
Aurinia reiterates its guidance for 2026 total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and 2026 net product sales of $305 million to $315 million, up 12% to 16% compared to 2025.
“Aurinia remains steadfast in its mission to become a leading company that benefits patients suffering from autoimmune diseases,” stated Kevin Tang, Chief Executive Officer. “LUPKYNIS is emerging as a standard-of-care treatment for lupus nephritis, and aritinercept, now in clinical development for three potential indications, has therapeutic potential across a wide range of autoimmune disorders.”
About Aurinia
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS®
(voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.¹
Financial statements
Income Statement
Three Months Ended — (in thousands, except per share data)
| Three Months Ended – March 31, – 2026 | 2025 | ||
|---|---|---|---|
| Revenue | Net product sales | 73,563 | 59,971 |
| Revenue | License, collaboration and royalty revenue | 4,142 | 2,494 |
| Revenue | Total revenue | 77,705 | 62,465 |
| Operating expenses | Cost of revenue | 6,505 | 8,574 |
| Operating expenses | Selling, general and administrative | 22,029 | 20,339 |
| Operating expenses | Research and development | 7,470 | 5,743 |
| Operating expenses | Restructuring | 1,533 | |
| Operating expenses | Other expense, net | 279 | 4,429 |
| Operating expenses | Total operating expenses | 36,283 | 40,618 |
| Operating expenses | Income from operations | 41,422 | 21,847 |
| Operating expenses | Interest income | 3,515 | 3,569 |
| Operating expenses | Interest expense | -1,012 | -1,067 |
| Operating expenses | Net income before income taxes | 43,925 | 24,349 |
| Operating expenses | Income tax expense | 9,570 | 1,005 |
| Operating expenses | Net income | 34,355 | 23,344 |
| Earnings per share | Basic | 0.26 | 0.17 |
| Earnings per share | Diluted | 0.25 | 0.16 |
| Shares used in computing earnings per share | Basic | 132,375 | 138,917 |
| Shares used in computing earnings per share | Diluted | 137,639 | 143,199 |
Balance Sheet
March 31, 2026 — (in thousands)
| March 31, 2026 – (Unaudited) | December 31, 2025 | ||
|---|---|---|---|
| Current assets: | Cash, cash equivalents and restricted cash | 41,008 | 80,213 |
| Current assets: | Short-term investments | 337,775 | 317,784 |
| Current assets: | Accounts receivable, net | 49,175 | 41,454 |
| Current assets: | Inventory | 46,410 | 45,690 |
| Current assets: | Prepaid expenses and deposits | 4,119 | 5,746 |
| Current assets: | Other current assets | 1,757 | 1,080 |
| Current assets: | Total current assets | 480,244 | 491,967 |
| Current assets: | Deferred tax assets, net | 166,917 | 176,194 |
| Current assets: | Finance right-of-use lease assets | 69,508 | 73,865 |
| Current assets: | Intangible assets, net | 3,590 | 3,761 |
| Current assets: | Operating right-of-use lease assets | 1,659 | 3,596 |
| Current assets: | Property and equipment, net | 1,986 | 2,111 |
| Current assets: | Other noncurrent assets | 93 | 93 |
| Current assets: | Total assets | 723,997 | 751,587 |
| Current liabilities: | Accounts payable | 2,661 | 3,313 |
| Current liabilities: | Accrued expenses | 58,196 | 66,621 |
| Current liabilities: | Finance lease liabilities, current portion | 16,519 | 16,523 |
| Current liabilities: | Deferred revenue | 5,036 | 3,720 |
| Current liabilities: | Operating lease liabilities, current portion | 1,622 | 1,067 |
| Current liabilities: | Other current liabilities | 2,522 | 2,480 |
| Current liabilities: | Total current liabilities | 86,556 | 93,724 |
| Current liabilities: | Finance lease liabilities, less current portion | 48,181 | 52,322 |
| Current liabilities: | Deferred revenue, less current portion | 12,413 | 12,648 |
| Current liabilities: | Deferred compensation and other noncurrent liabilities | 6,903 | 6,662 |
| Current liabilities: | Operating lease liabilities, less current portion | 2,318 | 4,900 |
| Current liabilities: | Total liabilities | 156,371 | 170,256 |
| Shareholders' equity | Common shares — no par value, unlimited shares authorized, 130,771 and 132,323 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 1,086,650 | 1,120,035 |
| Shareholders' equity | Additional paid-in capital | 96,869 | 111,263 |
| Shareholders' equity | Accumulated other comprehensive loss | -880 | -599 |
| Shareholders' equity | Accumulated deficit | -615,013 | -649,368 |
| Shareholders' equity | Total shareholders' equity | 567,626 | 581,331 |
| Shareholders' equity | Total liabilities and shareholders' equity | 723,997 | 751,587 |
Cash Flow
Three Months Ended March 31, — (in thousands)
| Three Months Ended March 31, – 2026 | Three Months Ended March 31, – 2025 | ||
|---|---|---|---|
| Cash flows from operating activities: | Net income | 34,355 | 23,344 |
| Adjustments to reconcile net income to cash flows from operating activities: | Deferred income tax | 9,277 | |
| Adjustments to reconcile net income to cash flows from operating activities: | Share-based compensation | -866 | -3,409 |
| Adjustments to reconcile net income to cash flows from operating activities: | Amortization and depreciation | 4,816 | 4,856 |
| Adjustments to reconcile net income to cash flows from operating activities: | Foreign exchange (gain) loss on revaluation of Monoplant finance lease liability | -416 | 1,812 |
| Adjustments to reconcile net income to cash flows from operating activities: | Net amortization of premiums and discounts on investments | -2,319 | -2,656 |
| Adjustments to reconcile net income to cash flows from operating activities: | Other, net | 581 | 2,325 |
| Net changes in operating assets and liabilities: | Accounts receivable, net | -7,721 | -3,806 |
| Net changes in operating assets and liabilities: | Inventory | -720 | -6,967 |
| Net changes in operating assets and liabilities: | Prepaid expenses and other current assets | 950 | 6,033 |
| Net changes in operating assets and liabilities: | Accounts payable | -652 | -974 |
| Net changes in operating assets and liabilities: | Accrued expenses and other liabilities | -5,592 | -23,405 |
| Net changes in operating assets and liabilities: | Deferred revenue | 1,081 | 4,342 |
| Net changes in operating assets and liabilities: | Operating lease liabilities | -214 | -195 |
| Net changes in operating assets and liabilities: | Cash flows from operating activities | 32,560 | 1,300 |
| Cash flows from investing activities: | Proceeds from the sale and maturities of investments | 109,000 | 123,035 |
| Cash flows from investing activities: | Purchases of investments | -127,041 | -91,986 |
| Cash flows from investing activities: | Purchases of property, equipment and intangible assets | -39 | -17 |
| Cash flows from investing activities: | Cash flows from investing activities | -18,080 | 31,032 |
| Cash flows from financing activities: | Purchase of common shares under Share Repurchase Plan | -36,165 | -46,921 |
Full release
Forward-Looking Statements
This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: LUPKYNIS net product sales, the timing of clinical study results and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, and on Aurinia’s website at www.auriniapharma.com.
General Investor Inquiries ir@auriniapharma.com²